Table 1 Comparison of baseline characteristics between irAEs and non - irAEs groups
variables | irAEs (n = 27) | non-irAEs (n = 85) | χ2/Z | p value |
|---|---|---|---|---|
gender | Â | Â | 0.559 | 0.455 |
 male | 14(51.9%) | 51(60%) |  |  |
 female | 13(48.1%) | 34(40%) |  |  |
age (years) | Â | Â | 0.492 | 0.483 |
 < 60 | 10(37.0%) | 38(44.7%) |  |  |
 ≥ 60 | 17(63.0%) | 47(55.3%) |  |  |
BMI | 20.9122 ± 1.91697 | 21.6695 ± 3.10683 | -0.862 | 0.388 |
smoking history | Â | Â | 1.016 | 0.313 |
 yes | 7(25.8%) | 31(36.5%) |  |  |
 no | 20(74.1%) | 54(63.6%) |  |  |
ECOG-PS | Â | Â | 0.634 | 0.426 |
 0–1 | 26(96.3%) | 77(91.8%) |  |  |
 ≥ 2 | 1(3.7%) | 7(8.2%) |  |  |
Histology | Â | Â | 0.649 | 0.420 |
 Adenocarcinoma | 24(88.9%) | 70(82.4%) |  |  |
 Squamous carcinoma | 3(11.1%) | 15(17.3%) |  |  |
Line of treatment with ICIs | Â | Â | 0.000 | 0.994 |
 1 | 14(51.9%) | 44(51.8%) |  |  |
 ≥ 2 | 13(48.1%) | 41(48.2%) |  |  |
Gene mutation | Â | Â | 0.821 | 0.365 |
 Yes | 8(29.6%) | 18(21.2%) |  |  |
 No | 19(70.4%) | 67(78.8%) |  |  |
Treatment data | Â | Â | 1.195 | 0.550 |
 Monotherapy | 3(11.1%) | 12(14.1%) |  |  |
 Combination with chemotherapy | 21(77.8%) | 57(67.1%) |  |  |
 Combination with other treatments | 3(11.1%) | 16(18.8%) |  |  |